MetaVia Inc. (MTVA)
NASDAQ: MTVA
· Real-Time Price · USD
0.77
0.01 (1.05%)
At close: May 02, 2025, 3:59 PM
0.79
2.46%
After-hours: May 02, 2025, 05:53 PM EDT
1.05% (1D)
| Bid | 0.74 |
| Market Cap | 7.78M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -27.59M |
| EPS (ttm) | -3.56 |
| PE Ratio (ttm) | -0.22 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.82 |
| Volume | 210,516 |
| Avg. Volume (20D) | 484,595 |
| Open | 0.74 |
| Previous Close | 0.76 |
| Day's Range | 0.73 - 0.79 |
| 52-Week Range | 0.65 - 5.30 |
| Beta | 0.22 |
About MTVA
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of ...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 5, 2016
Employees 9
Stock Exchange NASDAQ
Ticker Symbol MTVA
Website https://www.metaviatx.com
Analyst Forecast
According to 1 analyst ratings, the average rating for MTVA stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 1456.42% from the latest price.
Stock Forecasts2 weeks ago
-55.98%
MetaVia shares are trading lower. The company anno...
Unlock content with
Pro Subscription